These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 21295398)
21. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Rini BI; Flaherty K Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471 [TBL] [Abstract][Full Text] [Related]
22. Temsirolimus (Torisel) for advanced renal cell carcinoma. Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154 [No Abstract] [Full Text] [Related]
23. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma. Gardner TA; Logan T J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946 [No Abstract] [Full Text] [Related]
24. Phase II cytotoxic chemotherapy trials in renal cell carcinoma: 1983-1988. Yagoda A Prog Clin Biol Res; 1990; 350():227-41. PubMed ID: 2201045 [No Abstract] [Full Text] [Related]
25. Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial. Gams RA; Nelson O; Birch R Cancer Treat Rep; 1986 Jul; 70(7):921-2. PubMed ID: 3521848 [No Abstract] [Full Text] [Related]
26. Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review. Kamada P; Dudek AZ Cancer Invest; 2010 Jun; 28(5):501-4. PubMed ID: 20014944 [TBL] [Abstract][Full Text] [Related]
30. Targeted therapy for renal cell cancer: current perspectives. van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471 [TBL] [Abstract][Full Text] [Related]
31. Transient perforating folliculitis induced by sorafenib. Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372 [No Abstract] [Full Text] [Related]
32. Targeted for destruction: the molecular basis for development of novel therapeutic strategies in renal cell cancer. Srinivasan R; Linehan WM J Clin Oncol; 2005 Jan; 23(3):410-2. PubMed ID: 15572728 [No Abstract] [Full Text] [Related]
33. Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy. Kishida T; Yao M; Uemura H; Ohlmann C; Tomita Y; Bukowski RM; Naito S Int J Urol; 2010 Mar; 17(3):198-205. PubMed ID: 20409215 [No Abstract] [Full Text] [Related]
34. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Bellmunt J; Fishman M; Eisen T; Quinn D Expert Rev Anticancer Ther; 2010 Jun; 10(6):825-35. PubMed ID: 20553208 [TBL] [Abstract][Full Text] [Related]
35. Molecularly targeted agents for renal cell carcinoma: the next generation. Cowey CL; Hutson TE Clin Adv Hematol Oncol; 2010 May; 8(5):357-60, 361-4. PubMed ID: 20551895 [TBL] [Abstract][Full Text] [Related]
37. Editorial comment on: update on the medical treatment of metastatic renal cell carcinoma. Ficarra V; Novara G Eur Urol; 2008 Aug; 54(2):324-5. PubMed ID: 18485580 [No Abstract] [Full Text] [Related]
38. Editorial comment on: update on the medical treatment of metastatic renal cell carcinoma. Van Poppel H Eur Urol; 2008 Aug; 54(2):324. PubMed ID: 18485572 [No Abstract] [Full Text] [Related]